THERAPY FOR UROGENITAL DISORDERS AFTER SURGICAL MENOPAUSE

Objective. To examine and treat 30 women with urogenital disorders (UGD) after surgical menopause. Subjects and methods. Along with the symptoms of vaginal atrophy, different forms of urinary incontinence (UI) were observed in the majority (n = 18) of the 30 patients: there was stress UI in 7 patients and its mixed form in 11. If normocenosis and vaginal atrophy were present, ovestin was recommended according to the following scheme: one suppository daily for 4 weeks, then one suppository twice weekly for 22 weeks as maintenance therapy. Soption combination therapy was performed in patients with bacterial vaginosis, nonspecific vaginitis, and Candida vaginitis. Moreover, the organic silicone sorbent oral enterosgel and hydrogel of this agent for intravaginal use with probiotics (bifidum, lactobacteria, acilactum, zhlemic) were used for 7-10 days. Ovestin suppositories were applied after vaginal sanitation. Results. Intravaginal ovestin used in patients with UGD after surgical menopause makes it possible to eliminate genital disorders and stress UI and the use of tolterodine promotes the abolishment of urge incontinence.

surgical menopause, urogenital disorders, ovestin